Gene therapy restores hearing to children with inherited deafness

Overall reaction

• Many express awe at gene therapy that restores hearing in children and see it as “real” breakthrough tech, not just software.
• Some share personal connections (family genetic hearing loss, ALS, screened embryos) and see this as concrete hope for current or future children.

How the therapy works (as discussed)

• Participants describe AAV vectors delivering a working OTOF gene into inner-ear cells.
• One explanation (later corrected) claimed AAV integrates into chromosomes; follow‑ups clarify AAV usually forms episomes (extra-chromosomal circles), which is why it’s considered safer.
• Clarifications on permanence: integrated DNA is inherited by daughter cells; episomes are long‑lasting but not germline edits.

Prospects and limits of gene editing

• Enthusiasm for “gene CAD” tools, CRISPR design assistants, and existing bio-CAD software (metabolic modeling, plasmid design, generative protein design).
• Some fantasize about radical body redesign (wings, species transition, new senses), while others argue physics, development, metabolism, and pain make such metamorphosis near-impossible or non-human in outcome.
• Discussion of whole-body, permanent editing notes major current obstacles: delivery vectors, organ targeting, toxicity, gene size limits, blood–brain barrier.

Deafness, disability, and ethics

• Debate over whether deafness is a “defect” to be fixed versus a valid identity and culture.
• Strong disagreement about parents declining interventions (e.g., cochlear implants) for children; some call it akin to child abuse, others stress procedure risks and consent.
• Comparisons drawn to LGBTQ identity and to left-handedness; participants argue over what counts as “objective disadvantage.”

Inheritance, IVF, and eugenics worries

• Concern that treated individuals can still pass on recessive deafness alleles; others note autosomal recessive risk is limited and IVF with preimplantation genetic testing can reduce such disorders.
• Some fear slippery slopes to eugenics; others argue selective embryo implantation already does “screening.”

Access, patents, and incentives

• Disagreement on patents and “rent-seeking”: some want Salk-style open sharing; others argue incentives are needed but current IP systems encourage monopoly and lobbying.
• Worries about dependence on expensive corporate therapies versus calls for better healthcare systems and broader funding.